Selected article for: "male beagle and washout period"
Title: 2017 ACVIM Forum Research Abstract Program
  • Document date: 2017_6_15
    • ID: ri2w5iby_682
    Snippet: Twelve healthy adult male Beagle dogs were included in this study. Both studies used an open, randomized, crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC) and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medicatio.....
    Document: Twelve healthy adult male Beagle dogs were included in this study. Both studies used an open, randomized, crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC) and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs.

    Search related documents:
    Co phrase search for related documents
    • adult male and efficacy study: 1
    • adult male and oral dose: 1, 2
    • adult male and plasma concentration: 1, 2, 3
    • adult male and randomized crossover design: 1
    • adult male and treatment period: 1
    • Beagle dog and oral dose: 1
    • crossover design and efficacy study: 1
    • crossover design and open randomized crossover design: 1, 2, 3
    • crossover design and oral dose: 1, 2, 3
    • crossover design and plasma concentration: 1, 2, 3, 4, 5
    • crossover design and randomized crossover design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
    • crossover design and study open randomized crossover design: 1
    • crossover design and treatment period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • crossover design and washout period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • efficacy study and oral dose: 1, 2, 3, 4, 5, 6, 7
    • efficacy study and PK study: 1, 2, 3, 4, 5, 6, 7
    • efficacy study and plasma concentration: 1, 2, 3, 4, 5, 6, 7
    • efficacy study and study include: 1, 2, 3, 4, 5, 6, 7, 8
    • efficacy study and treatment period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32